Johnson & Johnson Announces Investments of About $55 Million in U.S.

Johnson & Johnson has announced investments of over $55 million in the U.S. across manufacturing, research and development, and technology.

This represents a “25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act.” The investment begins with the ground-breaking of a new facility in Wilson, North Carolina.

Additionally, the investment will be put toward “three new advanced manufacturing facilities and the expansion of several existing sites across the Company’s Innovative Medicine and MedTech businesses that will create high-paying, high-technology jobs.” There will be “significant investments in extensive R&D infrastructure” aimed at developing treatments in areas like “oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.” The investment will also include “increased technology investments to help make drug discovery and development faster.”

The North Carolina facility will expand the company’s manufacturing capabilities for “cancer and immune-mediated and neurological diseases.” It will support “approximately 5,000 jobs during construction and create over 500 positions in North Carolina,” creating a $3 billion impact across the state in its first ten years of operation.